## **GSK plc (the 'Company')** Transaction notification

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Emma Walmsley	
b)	Position/status	Chief Executive Officer	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, auctioneer or auctio		narket participant, auction platform,
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D7	793
3.	Details of the transac (ii) each type of tran transaction(s) has be	saction; (iii) each date	repeated for (i) each type of instrument; ; and (iv) each place where
a)	Description of the financial instrument	Ordinary shares of 31 ½ ISIN: GB00BN7SWP63	4 pence each ('Ordinary Shares')
b)	Nature of the transaction	investment of dividends	terest in Ordinary Shares following the re- paid to shareholders on 10 April 2025 on the Company's Deferred Annual Bonus Plar
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£12.7500	1,304
		£12.7500	1,702
		£12.7500	1,924
d)	Aggregated information		
	Aggregated volume Price	4,930 £12.7500	
e)	Date of the transaction	2025-04-16	
f)	Place of the transaction	London Stock Exchang	e (XLON)

1.	Details of PDMR/pe	rson closely associated with them ('PCA')
a)	Name	Julie Brown
b)	Position/status	Chief Financial Officer
c)	Initial notification/ amendment	Initial notification

2. Details of the issuer, emission allowance market particip		ce market participant, auction platform,
aucuoneer or aucuo	II IIIOIIIIOI	
Name	GSK plc	
LEI	5493000HZTVUYLO	1D793
(ii) each type of trans	saction; (iii) each d	be repeated for (i) each type of instrument; ate; and (iv) each place where
		1 ¼ pence each ('Ordinary Shares') 263
	investment of divide	I interest in Ordinary Shares following the re- nds paid to shareholders on 10 April 2025 on d in the Company's Deferred Annual Bonus Plar
Price(s) and volume(s)	Price(s)	Volume(s)
	£12.7500	854
	£12.7500	734
Aggregated information		
00.00	,	
Date of the transaction	2025-04-16	
Place of the transaction	London Stock Exch	ange (XLON)
	auctioneer or auctio     Name     LEI     Details of the transaction (s) has been of the transaction (s) has been of the transaction of the financial instrument     Nature of the transaction     Nature of the transaction     Price(s) and volume(s)     Aggregated information     Aggregated volume Price     Date of the transaction     Place of the	auctioneer or auction monitorNameGSK plcLEI5493000HZTVUYLODetails of the transaction(s): section to I (ii) each type of transaction; (iii) each d transaction(s) has been conductedDescription of the financial instrumentOrdinary shares of 3 ISIN: GB00BN7SWFNature of the transactionIncrease in notional investment of divide Ordinary Shares heldPrice(s) and volume(s)Price(s) £12.7500Aggregated information1,588 £12.7500Aggregated volume price1,588 £12.7500Date of the transaction2025-04-16Place of the London Stock ExchangeLondon Stock Exchange

1.	Details of PDMR/person closely associated with them ('PCA')			
a)	Name	Diana Conrad		
b)	Position/status	Chief People Officer	Chief People Officer	
c)	Initial notification/ amendment	Initial notification		
2.	Details of the issue auctioneer or auct		narket participant, auction platform,	
a)	Name	GSK plc		
b)	LEI	5493000HZTVUYLO1D793		
2)				
3.		insaction; (iii) each date;	epeated for (i) each type of instrument; and (iv) each place where	
,	(ii) each type of tra	insaction; (iii) each date; been conducted		
3.	(ii) each type of tra transaction(s) has I Description of the	Ordinary shares of 31 1/4 ISIN: GB00BN7SWP63 Increase in notional interiorestment of dividends	and (iv) each place where	
<b>3.</b> a)	(ii) each type of tra transaction(s) has I Description of the financial instrument Nature of the	Insaction; (iii) each date; been conducted Ordinary shares of 31 ¼ ISIN: GB00BN7SWP63 Increase in notional inte investment of dividends Ordinary Shares held in t	and (iv) each place where pence each ('Ordinary Shares') erest in Ordinary Shares following the re- paid to shareholders on 10 April 2025 on	
a)	(ii) each type of tra transaction(s) has I Description of the financial instrument Nature of the transaction	Insaction; (iii) each date; been conducted Ordinary shares of 31 ¼ ISIN: GB00BN7SWP63 Increase in notional inte investment of dividends Ordinary Shares held in t	and (iv) each place where pence each ('Ordinary Shares') erest in Ordinary Shares following the re- paid to shareholders on 10 April 2025 on the Company's Deferred Annual Bonus Plan	
a)	(ii) each type of tra transaction(s) has I Description of the financial instrument Nature of the transaction	Insaction; (iii) each date;     been conducted     Ordinary shares of 31 ¼     ISIN: GB00BN7SWP63     Increase in notional intervestment of dividends     Ordinary Shares held in f     (s)   Price(s)	and (iv) each place where pence each ('Ordinary Shares') erest in Ordinary Shares following the re- paid to shareholders on 10 April 2025 on the Company's Deferred Annual Bonus Plan Volume(s)	

d)	Aggregated information	
	Aggregated volume Price	985 £12.7500
e)	Date of the transaction	2025-04-16
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	James Ford	
b)	Position/status	SVP and Group Gene	ral Counsel, Legal and Compliance
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, auctioneer or auctio		e market participant, auction platform,
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO11	D793
3.		saction; (iii) each da	e repeated for (i) each type of instrument; te; and (iv) each place where
a)	Description of the financial instrument	Ordinary shares of 31 ISIN: GB00BN7SWP6	¼ pence each ('Ordinary Shares') 33
b)	Nature of the transaction	investment of dividen	interest in Ordinary Shares following the re ds paid to shareholders on 10 April 2025 or in the Company's Deferred Annual Bonus Plar
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£12.7500	298
		£12.7500	491
		£12.7500	301
d)	Aggregated information		
	Aggregated volume Price	1,090 £12.7500	
e)	Date of the transaction	2025-04-16	
f)	Place of the transaction	London Stock Exchar	nge (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')	
a)	Name	Sally Jackson
b)	Position/status	SVP, Global Communications and CEO Office

c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, auctioneer or auctio	emission allowance market participant, auction platform, n monitor	
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1E	0793
3.	Details of the transac (ii) each type of tran transaction(s) has be	saction; (iii) each dat	repeated for (i) each type of instrument; e; and (iv) each place where
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re- investment of dividends paid to shareholders on 10 April 2025 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£12.7500	167
		£12.7500	304
		£12.7500	187
d)	Aggregated information		
	Aggregated volume Price	658 £12.7500	
e)	Date of the transaction	2025-04-16	
f)	Place of the transaction	London Stock Exchan	ge (XLON)

1.	Details of PDMR/pers	son closely associated v	with them ('PCA')
a)	Name	Luke Miels	
b)	Position/status	Chief Commercial Officer	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, auctioneer or auctio		arket participant, auction platform,
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re- investment of dividends paid to shareholders on 10 April 2025 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s)

		£12.7500 £12.7500	914 726	
d)	Aggregated information			
	Aggregated volume Price	2,098 £12.7500		
e)	Date of the transaction	2025-04-16		
f)	Place of the transaction	London Stock Exchan	ge (XLON)	

1.	Details of PDMR/per	son closely associated	with them ('PCA')
a)	Name	Shobie Ramakrishnan	
b)	Position/status	Chief Digital and Techno	logy Officer
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, auctioneer or auctio		narket participant, auction platform,
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D7	93
3.		saction; (iii) each date	epeated for (i) each type of instrument; ; and (iv) each place where
a)	Description of the financial instrument	American Depositary Sl ISIN: US37733W2044	ares ('ADSs')
b)	Nature of the transaction		erest in ADSs following the re-investment o olders on 10 April 2025 on ADSs held in the nual Bonus Plan
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		33.6000	134
		33.6000	222
		33.6000	143
d)	Aggregated information		
	Aggregated volume Price	499 33.6000	
e)	Date of the transaction	2025-04-16	
f)	Place of the transaction	New York Stock Excha	nge (XNYS)

1.

a)	Name	David Redfern	
b)	Position/status	President, Corporate	e Development
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, auctioneer or auctio		ce market participant, auction platform,
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO	1D793
3.	Details of the transac (ii) each type of trans transaction(s) has be	saction; (iii) each d	be repeated for (i) each type of instrument; ate; and (iv) each place where
a)		Ordinary shares of 3 ISIN: GB00BN7SWF	1 ¼ pence each ('Ordinary Shares') 263
b)	transaction	Increase in notional interest in Ordinary Shares following the re- investment of dividends paid to shareholders on 10 April 2025 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£12.7500	265
		£12.7500	581
		£12.7500	419
d)	Aggregated information		
	55 5	1,265 £12.7500	
e)	Date of the transaction	2025-04-16	
f)	Place of the transaction	London Stock Exch	ange (XLON)

1.	Details of PDMR/pe	erson closely associated with them ('PCA')
a)	Name	Regis Simard
b)	Position/status	President, Global Supply Chain
c)	Initial notification/ amendment	Initial notification
2.	Details of the issue auctioneer or aucti	r, emission allowance market participant, auction platform, on monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.		action(s): section to be repeated for (i) each type of instrument; nsaction; (iii) each date; and (iv) each place where been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63

b)		investment of dividend	nterest in Ordinary Shares following the re- ds paid to shareholders on 10 April 2025 on in the Company's Deferred Annual Bonus Plan
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£12.7500	388
		£12.7500	337
		£12.7500	700
d)	Aggregated information		
	Aggregated volume Price	1,425 £12.7500	
e)	Date of the transaction	2025-04-16	
f)	Place of the transaction	London Stock Exchar	ge (XLON)

1.	Details of PDMR/pers	son closely associated v	vith them ('PCA')
a)	Name	Philip Thomson	
b)	Position/status	President, Global Affairs	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, auctioneer or auctio		arket participant, auction platform,
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D79	3
3.		saction; (iii) each date;	peated for (i) each type of instrument; and (iv) each place where
a)	Description of the financial instrument	Ordinary shares of 31 ¼ p ISIN: GB00BN7SWP63	pence each ('Ordinary Shares')
b)	Nature of the transaction	investment of dividends p	rest in Ordinary Shares following the re- oaid to shareholders on 10 April 2025 on he Company's Deferred Annual Bonus Plan
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£12.7500	236
		£12.7500	391
		£12.7500	220
d)	Aggregated information		
	Aggregated volume Price	847 £12.7500	
e)	Date of the transaction	2025-04-16	

f)

1.   Details of PDMR/person closely associated with them ('PCA')     a)   Name   Deborah Waterhouse     b)   Position/status   CEO, ViiV Healthcare and President, Global Health, GSK     c)   Initial notification/ amendment   Initial notification     a)   Name   GSK plc     b)   LEI   5493000HZTVUYLO1D793     3.   Details of the transaction(s): section to be repeated for (i) each type of instrum (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted     a)   Description of the financial instrument   Ordinary shares of 31 ¼ pence each (Ordinary Shares') [SIN: GB00BN7SWP63     b)   Nature of the transaction   Increase in notional interest in Ordinary Shares following 1 investment of dividends paid to shareholders on 10 April 2 Ordinary Shares held in the Company's Deferred Annual Bonu     c)   Price(s) and volume(s)   Price(s)   Volume(s)     £12.7500   537     £12.7500   606     c)   Aggregated volume price   1,508     evel of the transaction   1,508     f12.7500   606     information   1,508     evel of the transaction   2025-04-16     f)   Place of the transaction					
b)   Position/status   CEO, ViiV Healthcare and President, Global Health, GSK     c)   Initial notification/ amendment   Initial notification     2.   Details of the issuer, emission allowance market participant, auction platform auctioneer or auction monitor     a)   Name   GSK plc     b)   LEI   5493000HZTVUYLO1D793     3.   Details of the transaction(s): section to be repeated for (i) each type of instrum (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted     a)   Description of the financial instrument   Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63     b)   Nature of the transaction   Increase in notional interest in Ordinary Shares following 1 investment of dividends paid to shareholders on 10 April 2 Ordinary Shares held in the Company's Deferred Annual Bonu     c)   Price(s) and volume(s)   Price(s)   Volume(s)     £12.7500   537     £12.7500   606     d)   Aggregated volume Price   1,508     Price   12.7500   606     e)   Date of the transaction   1,508     f)   Place of the   London Stock Exchange (XLON)	1.	Details of PDMR/per	son closely	associated with	th them ('PCA')
b)   Position/status   CEO, ViiV Healthcare and President, Global Health, GSK     c)   Initial notification/ amendment   Initial notification     2.   Details of the issuer, emission allowance market participant, auction platform auctioneer or auction monitor     a)   Name   GSK plc     b)   LEI   5493000HZTVUYLO1D793     3.   Details of the transaction(s): section to be repeated for (i) each type of instrum (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted     a)   Description of the financial instrument   Ordinary shares of 31 ½ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63     b)   Nature of the transaction   Increase in notional interest in Ordinary Shares following 1 investment of dividends paid to shareholders on 10 April 2 Ordinary Shares held in the Company's Deferred Annual Bonu     c)   Price(s) and volume(s)   Price(s)   Volume(s)     £12.7500   537     £12.7500   606     d)   Aggregated volume Price   1,508     Price   12.7500   606     e)   Date of the transaction   2025-04-16     f)   Place of the   London Stock Exchange (XLON)					
c)   Initial notification/ amendment   Initial notification     2.   Details of the issuer, emission allowance market participant, auction platform auctioneer or auction monitor     a)   Name   GSK plc     b)   LEI   5493000HZTVUYLO1D793     3.   Details of the transaction(s): section to be repeated for (i) each type of instrum (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted     a)   Description of the financial instrument   Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63     b)   Nature of the transaction   Increase in notional interest in Ordinary Shares following to investment of dividends paid to shareholders on 10 April 20 Ordinary Shares held in the Company's Deferred Annual Bonu     c)   Price(s) and volume(s)   Price(s)   Volume(s)     £12.7500   537     £12.7500   606     d)   Aggregated information   1,508     Aggregated volume Price   1,508     £12.7500   606     f)   Place of the transaction   2025-04-16     f)   Place of the   London Stock Exchange (XLON)	a)	Name	Deborah Wa	aterhouse	
amendment   amendment     2.   Details of the issuer, emission allowance market participant, auction platform auctioneer or auction monitor     a)   Name   GSK plc     b)   LEI   5493000HZTVUYLO1D793     3.   Details of the transaction(s): section to be repeated for (i) each type of instrum (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted     a)   Description of the financial instrument   Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63     b)   Nature of the transaction   Ordinary shares of 31 ¼ pence each ('Ordinary Shares following threas the of dividends paid to shareholders on 10 April 20 Ordinary Shares held in the Company's Deferred Annual Bonu     c)   Price(s) and volume(s)   Price(s)   Volume(s)     £12.7500   537   £12.7500   537     £12.7500   537   £12.7500   606     d)   Aggregated volume Price   1,508   £12.7500   606     e)   Date of the transaction   2025-04-16   2025-04-16     f)   Place of the   London Stock Exchange (XLON)   1	b)	Position/status	CEO, ViiV H	lealthcare and I	President, Global Health, GSK
auctioneer or auction monitor     a)   Name   GSK plc     b)   LEI   5493000HZTVUYLO1D793     3.   Details of the transaction(s): section to be repeated for (i) each type of instrum (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted     a)   Description of the financial instrument   Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63     b)   Nature of the transaction   Increase in notional interest in Ordinary Shares following to investment of dividends paid to shareholders on 10 April 20 Ordinary Shares held in the Company's Deferred Annual Bonu     c)   Price(s) and volume(s)   Price(s)   Volume(s)     £12.7500   537     £12.7500   537     £12.7500   606     d)   Aggregated volume Price   1,508     £12.7500   E12.7500     e)   Date of the transaction   2025-04-16     f)   Place of the   London Stock Exchange (XLON)	c)		Initial notifica	ation	
b)   LEI   5493000HZTVUYL01D793     3.   Details of the transaction(s): section to be repeated for (i) each type of instrum (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted     a)   Description of the financial instrument   Ordinary shares of 31 ¼ pence each (Ordinary Shares')     b)   Nature of the transaction   Increase in notional interest in Ordinary Shares following 1 investment of dividends paid to shareholders on 10 April 20 Ordinary Shares held in the Company's Deferred Annual Bonu     c)   Price(s) and volume(s)   Price(s)   Volume(s)     £12.7500   365     £12.7500   537     £12.7500   606     d)   Aggregated volume Price   1,508     £12.7500   E12.7500     e)   Date of the transaction   2025-04-16     f)   Place of the   London Stock Exchange (XLON)	2.			llowance mar	ket participant, auction platform,
3.   Details of the transaction(s): section to be repeated for (i) each type of instrum (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted     a)   Description of the financial instrument   Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63     b)   Nature of the transaction   Increase in notional interest in Ordinary Shares following to investment of dividends paid to shareholders on 10 April 20 Ordinary Shares held in the Company's Deferred Annual Bonu     c)   Price(s) and volume(s)   Price(s)   Volume(s)     £12.7500   537     £12.7500   537     £12.7500   606     d)   Aggregated information     Aggregated volume Price   1,508     £12.7500   2025-04-16     f)   Place of the transaction	a)	Name	GSK plc		
(ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted     a)   Description of the financial instrument   Ordinary shares of 31 ¼ pence each ('Ordinary Shares')     b)   Nature of the transaction   Increase in notional interest in Ordinary Shares following to investment of dividends paid to shareholders on 10 April 20 Ordinary Shares held in the Company's Deferred Annual Bonu     c)   Price(s) and volume(s)   Price(s)   Volume(s)     £12.7500   365     £12.7500   537     £12.7500   606     d)   Aggregated information   1,508     Price   1,508     £12.7500   2025-04-16     f)   Place of the   London Stock Exchange (XLON)	b)	LEI	5493000HZ1	VUYLO1D793	
financial instrument   ISIN: GB00BN7SWP63     b)   Nature of the transaction   Increase in notional interest in Ordinary Shares following to investment of dividends paid to shareholders on 10 April 20 Ordinary Shares held in the Company's Deferred Annual Bonu     c)   Price(s) and volume(s)   Price(s)   Volume(s)     £12.7500   365     £12.7500   537     £12.7500   606     d)   Aggregated information     Aggregated volume Price   1,508     £12.7500   2025-04-16     f)   Place of the     London Stock Exchange (XLON)	3.	(ii) each type of tran	saction; (iii)	each date; ar	eated for (i) each type of instrument Id (iv) each place where
transaction   investment of dividends paid to shareholders on 10 April 20     Ordinary Shares held in the Company's Deferred Annual Bonu     c)   Price(s) and volume(s)     £12.7500   365     £12.7500   537     £12.7500   606     d)   Aggregated information     Aggregated volume Price   1,508     £12.7500   2025-04-16     f)   Place of the     London Stock Exchange (XLON)	a)				nce each ('Ordinary Shares')
d)   Aggregated information     Aggregated volume Price   1,508 £12.7500     606	b)		investment (	of dividends pa	id to shareholders on 10 April 2025 of
a   E12.7500   537     £12.7500   606     d)   Aggregated information     Aggregated volume Price   1,508     £12.7500   500     e)   Date of the transaction     f)   Place of the     London Stock Exchange (XLON)	c)	Price(s) and volume(s)	Price(s)		Volume(s)
d) Aggregated information   Aggregated volume Price 1,508 £12.7500   e) Date of the transaction   f) Place of the   London Stock Exchange (XLON)			£12.7500	)	365
d)   Aggregated information     Aggregated volume Price   1,508 £12.7500     e)   Date of the transaction     f)   Place of the     London Stock Exchange (XLON)			£12.7500		537
information Aggregated volume 1,508   Price £12.7500   e) Date of the transaction 2025-04-16   f) Place of the London Stock Exchange (XLON)			£12.7500		606
Price £12.7500   e) Date of the transaction 2025-04-16   f) Place of the London Stock Exchange (XLON)	d)	Aggregated information			
transaction   f) Place of the   London Stock Exchange (XLON)			· ·		
·/ ···································	e)		2025-04-16		
	f)		London Stoc	ck Exchange (X	LON)

1.	Details of PDMR/pe	erson closely associated with them ('PCA')
a)	Name	Tony Wood
b)	Position/status	Chief Scientific Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issue auctioneer or auct	er, emission allowance market participant, auction platform, tion monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.		saction(s): section to be repeated for (i) each type of instrument; ansaction; (iii) each date; and (iv) each place where been conducted

a)	Description of the		pence each ('Ordinary Shares')
	financial instrument	ISIN: GB00BN7SWP63	
b)		investment of dividends	rest in Ordinary Shares following the re- paid to shareholders on 10 April 2025 on he Company's Deferred Annual Bonus Plan
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£12.7500	340
		£12.7500	254
		£12.7500	746
d)	Aggregated information		
	Aggregated volume Price	1,340 £12.7500	
e)	Date of the transaction	2025-04-16	
f)	Place of the transaction	London Stock Exchange	(XLON)

1.	Details of PDMR/per	son closely assoc	iated with them ('PCA')	
a)	Name	Emma Walmsley		
b)	Position/status	Chief Executive C	fficer	
c)	Initial notification/ amendment	Initial notification		
2.	Details of the issuer, auctioneer or auction		nce market participant, auct	ion platform,
a)	Name	GSK plc		
b)	LEI	5493000HZTVUYI	_01D793	
3.		saction; (iii) each	o be repeated for (i) each typ ı date; and (iv) each place w	
a)	Description of the financial instrument	Ordinary shares c ISIN: GB00BN7S\	f 31 ¼ pence each ('Ordinary S WP63	hares')
b)	Nature of the transaction	dividends paid to	inary Shares following the re-inv shareholders on 10 April 2025 o any's Performance Share Plan s	n Ordinary Shares
c)	Price(s) and volume(s	) Price(s)	Volume(s)	
		£12.7500	11,184.930	
			,	]

d)	Aggregated information Aggregated volume Price	NA (single transaction)	
e)	Date of the transaction	2025-04-16	
f)	Place of the transaction	London Stock Exchange (XLON)	

1.	Details of PDMR/per	son closely associated	with them ('PCA')
a)	Name	Dr Hal Barron	
b)	Position/status	Non-Executive Director	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, auctioneer or auctio		narket participant, auction platform,
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D7	93
3.		saction; (iii) each date	epeated for (i) each type of instrument; ; and (iv) each place where
a)	Description of the financial instrument	American Depositary Sł ISIN: US37733W2044	ares ('ADSs')
b)	Nature of the transaction	Acquisition of ADSs foll shareholders on 10 Apri	owing the re-investment of dividends paid to 2025
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		35.9948	3603.574
d)	Aggregated information Aggregated volume Price	WA (single transaction)	
e)	Date of the transaction	2025-04-15	
f)	Place of the transaction	New York Stock Excha	nge (XNYS)

1.	Details of PDMR/p	erson closely associated with them ('PCA')
a)	Name	James Ford
b)	Position/status	SVP and Group General Counsel, Legal and Compliance
c)	Initial notification/ amendment	Initial notification
2.	Details of the issue	er, emission allowance market participant, auction platform,

	auctioneer or auctio	n monitor		
a)	Name	GSK plc		
b)	LEI	5493000HZTVUYLC	01D793	
3.	Details of the transac (ii) each type of trans transaction(s) has be	saction; (iii) each o		or (i) each type of instrument; ach place where
a)		American Deposita ISIN: US37733W20		s')
b)		Acquisition of ADS: shareholders on 10		-investment of dividends paid to
c)	Price(s) and volume(s)	Price(s)	V	/olume(s)
		35.9948	3	63.602
d)	Aggregated information Aggregated volume Price	N/A (single transac	tion)	
e)	Date of the transaction	2025-04-15		
f)	Place of the transaction	New York Stock Ex	change (XNYS)	

1.	Details of PDMR/pe	erson closely associated v	with them ('PCA')
a)	Name	Shobie Ramakrishnan	
b)	Position/status	Chief Digital and Technol	ogy Officer
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issue auctioneer or auct		arket participant, auction platform
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D79	13
3.	Details of the trans (ii) each type of tra transaction(s) has	ansaction; (iii) each date;	and (iv) each place where
<b>3</b> . a)	(ii) each type of tra	ansaction; (iii) each date;	
	(ii) each type of tra transaction(s) has Description of the	Amsaction; (iii) each date; been conducted American Depositary Sha ISIN: US37733W2044	and (iv) each place where ares ('ADSs') wing the re-investment of dividends pa
a)	(ii) each type of tra transaction(s) has Description of the financial instrument Nature of the	American Depositary Sha ISIN: US37733W2044 Acquisition of ADSs follor shareholders on 10 April	and (iv) each place where ares ('ADSs') wing the re-investment of dividends pa
a) b)	(ii) each type of tra transaction(s) has Description of the financial instrument Nature of the transaction	American Depositary Sha Single American Depositary Sha ISIN: US37733W2044 Acquisition of ADSs follow shareholders on 10 April	and (iv) each place where ares ('ADSs') wing the re-investment of dividends pa 2025
a) b)	(ii) each type of tra transaction(s) has Description of the financial instrument Nature of the transaction	American Depositary Sha ISIN: US37733W2044 Acquisition of ADSs follor shareholders on 10 April (s) Price(s)	and (iv) each place where ares ('ADSs') wing the re-investment of dividends pa 2025

e)	Date of the transaction	2025-04-15
f)	Place of the transaction	New York Stock Exchange (XNYS)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact <a href="mailto:ms@lseg.com">ms@lseg.com</a> or visit <a href="mailto:www.ms.com">www.ms.com</a>.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our <u>Privacy Policy</u>.

END

DSHSFEFDWEISEIL